Horizon broadens industry-leading gene editing capabilities through extension of key CRISPR license and grant-funded research
CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics Announce Global Agreement on the Foundational Intellectual Property for CRISPR/Cas9 Gene Editing Technology
